BioSpace· Michael Gibney·· 3 hours agoPickScore68
Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
In brief
Gene therapies for Rett syndrome from Neurogene and Taysha have both entered the final stretch of late-stage development, with NGN-401 advancing in the pivotal Embolden trial and TSHA-102 in the pivotal REVEAL trial.
Why it matters
The article compares TSHA-102 and NGN-401 on delivery method, trial design, safety signals and regulatory timelines, providing a framework for two Rett gene therapy paths.
Source: BioSpace · biospace.com